Athletes using GLP-1 drugs like semaglutide are reporting unusual changes in cardiovascular metrics, prompting researchers to investigate what's driving these alterations. Resting heart rate, heart rate variability (HRV), and VO2 max readings are shifting unexpectedly in fit individuals taking these weight-loss medications, creating confusion about whether the devices are malfunctioning or the drugs are actually changing physiological performance.
GLP-1 receptor agonists work by slowing gastric emptying and suppressing appetite, leading to rapid weight loss. They've become popular among athletes seeking performance advantages or aesthetic improvements. However, fitness enthusiasts tracking their metrics with smartwatches and fitness trackers are seeing confusing data. Some report elevated resting heart rates despite improved fitness. Others observe HRV fluctuations inconsistent with their training load. VO2 max estimates sometimes drop even as users feel stronger.
The pattern suggests GLP-1s may alter cardiovascular function in ways not yet fully understood. These drugs affect more than appetite control. They influence insulin secretion, metabolic rate, and potentially cardiac performance itself. The medications can cause dehydration, which directly impacts heart rate measurements. Weight loss alone changes cardiovascular demands, potentially explaining some shifts in metrics.
Sports scientists and cardiologists are now examining whether GLP-1 use requires different interpretations of standard fitness data. The concern extends beyond measurement confusion. Some research hints that rapid weight loss combined with GLP-1 use might stress the cardiovascular system in ways that deserve clinical attention, particularly in younger, athletic populations.
Athletes considering these drugs should understand that smartwatch metrics may become unreliable during treatment. More importantly, they should consult cardiologists before starting GLP-1s, especially if engaged in high-intensity training. The fitness community is adapting rapidly, but the science is still